Navigation Links
Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results
Date:8/8/2011

ash expenditure for the second half of 2011, a viable path forward for Contrave, the timing of and potential for success with the dispute resolution process for Contrave, and the potential for, and timing of, approval for Contrave. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: Orexigen's ability to succeed in the dispute resolution process for Contrave; Orexigen's ability to agree with the FDA on the design and feasibility of a cardiovascular outcomes trial, Orexigen's ability to conduct such a cardiovascular outcomes trial, Orexigen's ability to demonstrate that the risk of major adverse cardiovascular events in overweight and obese subjects treated with Contrave does not adversely affect the product candidate's benefit-risk profile; the potential for early termination of the collaboration agreement between Orexigen and Takeda; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of an NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to attract and retain key personnel; Orexigen's ability to maintain sufficient capital; and other risks described in the Company's filings with the Securities and Exchange Commission.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Quarterly Report on Form 10-Q, which we intend to file with the Securities Exchange Commission this week and will be available from the SEC's w
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
7. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
11. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Thirty-six million Americans suffer from hearing loss, ... National Hearing Month – more than 28 million Americans ... the sounds of spring, like birds singing and the ... that you won,t be among those missing out on ... offers practical advice: Take action if you ...
(Date:5/4/2015)... -- Impax Laboratories, Inc. (NASDAQ: IPXL ) announced that ...  Donna M. Hughes, as Senior Vice President, Human Resources ... President, Chief Compliance Officer. Both Ms. Hughes and Ms. ... Officer, Fred Wilkinson . "We are ... team," said Fred Wilkinson , President and Chief ...
(Date:5/4/2015)... Bayer HealthCare (Bayer) has entered into an ... ISIS ) on ISIS-FXI Rx, an antisense investigational ... Under the agreement Bayer will further develop and commercialize ... need. As part of the clinical development program, Bayer ... in an appropriate patient community. "Bayer ...
Breaking Medicine Technology:It's Better Hearing Month 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
... Sept. 2 NewCardio (OTC Bulletin Board: NWCI ... Renz, Jr., NewCardio,s President and CEO, purchased 128,000 shares during ... weeks following the Company,s filing of its SEC Form 10-Q ... 2010. "As discussed on our August 12, ...
... SKILLMAN, N.J., Sept. 2 ConvaTec, a world-leading developer ... hospital care, announced today the introduction of a new, ... with Strengthening Fibers, now available in the U.S. and ... highly exuding chronic and acute wounds. The new dressing, ...
Cached Medicine Technology:NewCardio CEO Increases Equity Position 2NewCardio CEO Increases Equity Position 3NewCardio CEO Increases Equity Position 4ConvaTec Expands AQUACEL® Dressing Product Line With Introduction of New Ribbon Dressing 2ConvaTec Expands AQUACEL® Dressing Product Line With Introduction of New Ribbon Dressing 3ConvaTec Expands AQUACEL® Dressing Product Line With Introduction of New Ribbon Dressing 4
(Date:5/4/2015)... New York, NY (PRWEB) May 04, 2015 ... the 2015 International Champions Cup (ICC) . While ... the world and is held every four years, the International ... Last year, the tournament saw the all-time attendance record for ... Real Madrid from the Big House at the University of ...
(Date:5/4/2015)... City, OK and Seattle, WA (PRWEB) May 04, 2015 ... announced the formation of a collaboration to facilitate development ... number of ophthalmic disorders that lead to blindness, including ... to the MiDROPS™ formulation platform developed by EyeCRO, which ... the eye via a topical eyedrop. , Under ...
(Date:5/4/2015)... VA (PRWEB) May 04, 2015 Ticket Down ... at the John Paul Jones Arena in Charlottesville, VA. ... the history of the music business and this beloved performer ... Paul McCartney, the former member of two legendary groups: Wings ... in the music business since 2013 on the “Out There” ...
(Date:5/4/2015)... May 04, 2015 New findings released ... Tumor Association (ABTA) show that people diagnosed with a ... treatment options, including clinical trials, at the time of ... make difficult decisions about their course of treatment. The ... the first nationwide brain tumor volunteer network, the ABTA ...
(Date:5/4/2015)... 2015 Pricing Healthcare announces it ... one patient receiving care at St. George Surgical Center ... must be performed by July 15th, 2015, and the patient ... up front and forego the filing of insurance claims). , ... every year, and it devastates more and more individuals and ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 3Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 4Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:Paul McCartney Tickets at John Paul Jones Arena in Charlottesville, VA: Ticket Down Slashes Paul McCartney Ticket Prices in Charlottesville at the John Paul Jones Arena 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 3
... in patients with metastatic breast cancer, especially in those ... epidermal growth factor receptor-2) positive, a surgical oncologist will ... Breast Cancer Conference (EBCC7). Dr Marie Sundquist, ... will say that the median survival times for five-year ...
... ... leading Pediatrician Dr. William Lawrence Jr. of Sixty Second Parent encouraged parents to continue ... ... National Nutrition Month draws to a close, leading Pediatrician Dr. William Lawrence Jr. of ...
... ... of Shimmering Resumes, offers to help former Bush speechwriter David Frum with his resume. ... strategy on healthcare reform. , ... (PRWEB) March 26, 2010 -- Paul Freiberger, the President of Shimmering Resumes, ...
... ... accidents , ... March 26, 2010 -- With the arrival of spring, more cyclists are planning to enjoy the ... people sharing the road with drivers and pedestrians., , , , ,This week bikers complained to ...
... ... disorders and improve dental procedures. , ... Miami, FLA. (PRWEB) -- In addition to cosmetic dentistry services, including veneers and ... Institute now offer dental massage to patients. Dr. Nassery teams up with Love Life Massage, ...
... Women who discover they have breast cancer while they ... the health of their unborn baby, according to research ... Conference (EBCC7) in Barcelona today (Friday). Dr Sibylle ... University of Frankfurt, Germany, and a member of the ...
Cached Medicine News:Health News:Survival in metastatic breast cancer patients is improving: targeted therapies have contributed 2Health News:Eating Habits Start Early - Parents must be Good Role Models for Healthy Kids 2Health News:President of Shimmering Resumes Offers Professional Resume To Bush Speechwriter, David Frum 2Health News:New York Personal Injury Attorney Interprets Increase in Tickets for Cyclists as Effort to Make Streets Safer 2Health News:Top Miami Dentist, Dr. Hamid Nassery, Offers Dental Massage Services For Patients 2Health News:Pregnant women can receive breast cancer chemotherapy without endangering health of their babies 2Health News:Pregnant women can receive breast cancer chemotherapy without endangering health of their babies 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: